Candidate Human Genetic Polymorphisms and Severe Malaria in a Tanzanian Population

Alphaxard Manjurano1,2,*, Taane G. Clark2,3,*, Behzad Nadjm1,2, George Mtove1, Hannah Wangai1, Nuno Sepulveda3, Susana G. Campino4, Caroline Maxwell2, Raimos Olomi1, Kirk R. Rockett5, Anna Jeffreys5, MalariaGen Consortium, Eleanor M. Riley2, Hugh Reyburn1,2, Christopher Drakeley1,2,*. These authors contributed equally to this work.

1 Joint Malaria Programme, Kilimanjaro Christian Medical Centre, Moshi, Tanzania, 2 Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom, 5 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

Abstract

Human genetic background strongly influences susceptibility to malaria infection and progression to severe disease and death. Classical genetic studies identified haemoglobinopathies and erythrocyte-associated polymorphisms, as protective against severe disease. High throughput genotyping by mass spectrometry allows multiple single nucleotide polymorphisms (SNPs) to be examined simultaneously. We compared the prevalence of 65 human SNPs, previously associated with altered risk of malaria, between Tanzanian children with and without severe malaria. Five hundred children, aged 1–10 years, with severe malaria were recruited from those admitted to hospital in Muheza, Tanzania and compared with matched controls. Genotyping was performed by Sequenom MassArray, and conventional PCR was used to detect deletions in the alpha-thalassaemia gene. SNPs in two X-linked genes were associated with altered risk of severe malaria in females but not in males: heterozygosity for one or other of two SNPs in the G6PD gene was associated with protection from all forms of severe disease whilst two SNPs in the gene encoding CD40L were associated with respiratory distress. A SNP in the adenyl cyclase 9 (ADCY9) gene was associated with protection from acidosis whilst a polymorphism in the IL-1x gene (IL1A) was associated with an increased risk of acidosis. SNPs in the genes encoding IL-13 and reticulon-3 (RTN3) were associated with increased risk of cerebral malaria. This study confirms previously known genetic associations with protection from severe malaria (HbS, G6PD). It identifies two X-linked genes associated with altered risk of severe malaria in females, identifies mutations in ADCY9, IL1A and CD40L as being associated with altered risk of severe respiratory distress and acidosis, both of which are characterised by high serum lactate levels, and also identifies novel genetic associations with severe malaria (TRIM5) and cerebral malaria (IL-13 and RTN3). Further studies are required to test the generality of these associations and to understand their functional consequences.

Introduction

In spite of recent evidence of successful control in some countries [1,2,3], malaria still constitutes a major cause of child morbidity and mortality, especially in sub Saharan Africa [4,5]. Although the number of deaths from malaria remains high, the absolute risk of any particular infection progressing to severe disease is less than 1%, even in young children who appear to have similar, often low, levels of acquired immunity [6]. The risk factors for severe disease, and the reasons for the wide variation in clinical manifestations of malaria among children who appear to exhibit similar risks for severe disease, are poorly understood. This unexplained variation in disease severity and syndromic phenotype constitutes a major challenge to our understanding of the disease, its treatment and control.

Although parasite diversity, host age, acquired immunity and overall health status may all influence the risk of severe disease complications, it has been estimated that 25% of this risk can be accounted for by variations in host genotype [7]. The different geographic distributions of sickle-cell disease, α thalassaemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, ovalocytosis, and the Duffy-negative blood group are examples of the general principle that different populations have evolved different genetic variants to protect against malaria (see [8] for a review). The most striking example is the beta-globin HBB gene, in which three different coding SNPs confer protection against malaria:
Glu6Val (HbS), Glu6Lys (HbC), and Ghu26Lys (HbE). The HbS allele is common in Africa but rare in Southeast Asia, whereas the opposite is true for the HbE allele. In Tanzania, strong associations have been described between malaria transmission intensity and polymorphisms of both the HbS and alpha-thalassaemia genes [9]. In addition to the sickle polymorphism (HbS) [10], G6PD (reviewed in [11]), and ABO blood group [12,13], a number of other traits have been proposed for the reduced risk of severe malaria. Consistent with the view that severe malaria disease is, at least in part, an inflammatory process mediated by disordered immune responses [14] many of these traits are polymorphisms in genes that are relevant to immunity and inflammation such as the tumor necrosis factor (TNF, MHC class III region, reviewed in [15]), Toll-like receptors (TLR-4,9 [16], CD40 ligand (CD40L) [17], the interferon gamma (IFNG) (reviewed in [18]), and the Nitric oxide synthase type 2 (NOS2) genes (reviewed in [19]).

Here we test a panel of 65 SNPs, previously linked to altered risk of malaria or other infectious diseases, including the HbS and ABO polymorphisms, for association with severe malaria, and with the various clinical presentations of severe malarial disease. Our study is the first to comprehensively survey candidate SNPs in Tanzanians resident in a hyperendemic area of malaria with a high incidence of severe malaria disease and reveals X-linked polymorphisms that affect risk of severe disease in females but not in males, as well as polymorphisms in genes associated with inflammation, antigen processing and T cell function.

Methods
Ethics Statement
All DNA samples were collected and genotyped following signed and informed written consent from a parent or guardian. Ethics approval for all procedures was obtained from both LSHTM (# 2087) and the Tanzanian National Institute of Medical Research (NIMR/HQ/R.8a/Vol. IX/392).

Participants, Materials and Methods
Study participants. The study was conducted in Teule district hospital, Muheza, and surrounding villages in Muheza district, Tanga region, Tanzania, where mortality in children under 5 is estimated at 165 per 1000 (Tanzanian census 2002). Transmission of P. falciparum is intense (50–700 infected bites/person/year) and perennial, with two seasonal peaks. The community prevalence of P. falciparum in children aged 2–5 years in the study area was recorded as 88.2% in 2002 [20].

Cases were recruited during a one-year period between June 2006 and May 2007 as part of a larger study of severe febrile illness in children [detailed in [21,22]]. Among the children in the parent study, 509 cases of severe malaria were randomly sampled from children aged 6 months to 10 years meeting any one of the following eligibility criteria; history of 2 or more convulsions in the previous 24 hrs, prostration (unable to sit unsupported if <9 months of age or unable to drink at any age), reduced consciousness (Blantyre Coma scale<4), respiratory distress (deep breathing or indrawing of the lower chest wall), visible jaundice, severe anaemia (Hb <5 g/dL), acidosis (blood lactate ≥5 mmol/L) or hypoglycaemia (blood glucose <2.5 mmol/L). Parasite infection was confirmed by microscopic examination of Giemsa-stained thick blood films by two independent microscopists. Participants with known chronic medical conditions were excluded. Area of residence and ethnic origins of both parents were recorded from information provided by the caretaker of each child.

Controls were recruited during a 4 week period in August 2007 and were matched with cases for area of residence (ward), ethnicity and age, using household census data. Study participants resided in 33 wards surrounding Muheza town. The participants had a median age of ~2.6 years and belonged, predominantly, to one of eight ethnic groups (Table 1).

Sample collection & preparation. Approximately 3 ml of venous blood was collected from each participant into an EDTA vacutainer. A blood film was prepared and haemoglobin levels were measured by Hemocue (HemocueTM, Anglholm, Sweden). For children in the control group, those with haemoglobin levels of <11 g/dL and those with a positive blood film were excluded from genetic analysis and were referred to the nearest health

| Table 1. Baseline and clinical characteristics of cases and controls. |
|-----------------------------|-----------------------------|
| **Age** (median, range)     | Controls (n = 480)  | Cases (n = 507) |
|                             | (2.9) (0.9–10.9)   | (1.7) (0.2–10.0) |
| **Gender - Female**         | 258 53.8%     | 236 46.5%     |
| **Ward**                    |                |                |
| Mtimdirio                   | 40 8.3%        | 49 9.7%        |
| Kwafungo                    | 32 6.7%        | 43 8.5%        |
| Mikata                      | 32 6.7%        | 32 6.3%        |
| Kwelizinga                  | 30 6.3%        | 31 6.1%        |
| Songa                       | 25 5.2%        | 25 4.9%        |
| Nkumba                      | 21 4.4%        | 27 5.3%        |
| Segera                      | 23 4.8%        | 23 4.5%        |
| Maramba                     | 22 4.6%        | 21 4.1%        |
| Mhinduro                    | 20 4.2%        | 20 3.9%        |
| Potwe                       | 20 4.2%        | 20 3.9%        |
| Kilulu                      | 19 4.0%        | 19 3.7%        |
| Lusanga                     | 18 3.8%        | 18 3.6%        |
| Kicheba                     | 15 3.1%        | 18 3.6%        |
| Ngomeni                     | 16 3.3%        | 16 3.2%        |
| **Ethnicity**               |                |                |
| Mziguia                     | 159 33.1%      | 149 29.4%      |
| Wasambaa                    | 132 27.5%      | 131 25.8%      |
| Wabondei                    | 78 16.3%       | 79 15.6%       |
| Chagga                      | 50 10.4%       | 47 9.3%        |
| Mmbena                      | 23 4.8%        | 25 4.9%        |
| Other                       | 5 1.0%         | 39 7.7%        |
| Mngoni                      | 18 3.8%        | 19 3.7%        |
| Pare                        | 15 3.1%        | 18 3.6%        |
| **Clinical phenotype**      |                |                |
| Any severe malaria          | 507 100%       |                |
| Any SMA**                   | 247 48.7%      |                |
| Any CM                      | 99 19.5%       |                |
| Both SMA+CM                 | 41 8.1%        |                |
| Any RD                      | 146 28.8%      |                |
| Acidosis***                 | 291 57.4%      |                |

*In months, SMA = severe malarial anaemia, CM = cerebral malaria, RD = respiratory distress, **hb<5 gdl, ***Blood lactate>5 mmol/L.
facility where they were treated according to Tanzanian Ministry of Health guidelines. Samples were centrifuged at 5000 rpm for 5 minutes and the plasma removed and stored for future analysis. DNA was extracted and purified from the blood cell pellet using a Nucleon kit (http://www.tepnel.com) according to the manufacturer’s instructions.

Sample genotyping. Genomic DNA samples underwent whole genome amplification through either Primer Extension Pre-amplification (PEP) [23] or Multiple Displacement Amplification (MDA) [24], before genotyping on a Sequenom MassArray genotyping platform [25,26]. Sixty-five candidate SNPs (see supplementary Table 1) were selected for typing based on an extensive review of the published data and on emerging data from the MalariaGEN consortium (http://www.malariagen.net). The selected SNPs included Haemoglobin variant S (HbS) (rs334) as an anticipated positive control. The $a^{+}-thalassaemia deletion was typed separately by PCR [27].

Phenotypic definition. For analysis, subjects were defined as having had cerebral malaria (CM) if their Blantyre coma score was less than 3 on presentation to hospital. A second phenotypic subset of severe malarial anaemia (SMA) was defined as those subjects having had a haemoglobin concentration of less than 5 g/dL. Patients with both CM and SMA were included in the analysis for both phenotypes. Participants with co-existing severe illnesses diagnosed on admission, or with known chronic medical conditions unrelated to a severe malarial infection, were excluded. Other phenotypes of interest in severe malaria cases included respiratory distress and acidosis (blood lactate greater than $\geq 5 \text{ mmol/L}$). Because of sample size limitations, we do not present an analysis by ethnic groups or ward of residence.

Statistical analysis. Genotypic deviations from Hardy-Weinberg equilibrium (HWE) were assessed by chi-square tests. SNPs were excluded from analysis if they had at least 10% of genotype calls missing or there was significant deviation from HWE ($p < 0.001$) in controls. Case-control association analysis using SNP alleles/genotypes was undertaken by logistic regression and included the covariates: age, gender, ethnic group (or ward). We modelled the SNP of interest assuming several related genotypic mechanisms (additive, dominant, recessive, heterozygous advantage and general models) and reported the minimum p-value from these correlated tests. All haplotypes were phased using an expectation-maximisation algorithm [28]. All analyses were performed using the R statistical package (http://www.r-project.org). Performing multiple statistical tests leads to inflation in the occurrence of false positives and using a permutation approach that accounted for correlation between markers and tests, we estimated a p-value of $\leq 0.02$ to be statistically significant.

Results

Seven SNPs were removed from the analysis because they were either monomorphic (rs2814778, rs33950507, rs1799969, rs5743611, rs4986879, X_80140046), deviated from HWE in controls (rs1800750) or had high rates (>10%) of missing genotype
calls (rs1800750), leaving 58 SNPs which could be analysed for their association with severe malaria.

Figure 1 shows the minimum p-values from the genotypic tests applied to the autosomal SNPs, and confirms that the sickle cell (HbS) polymorphism (rs334) was significantly associated with protection from severe malaria (odds ratio (OR) AS vs AA/SS 0.055, 95% CI 0.022–0.140, p = 3e-18). Carriage of the HbS trait was also associated with protection from each of the different clinical phenotypes of severe malaria (Table 2 & Figure 2). Individuals who had a 3.7-thalassaemia deletion (in the additive model) were 30% less likely than individuals without this polymorphism to develop severe malarial anaemia (p = 0.01) but were not significantly protected against other forms of severe disease. There was no statistical interaction between carriage of the HbS trait and the 3.7 deletion and risk of any severe malaria complications (Table 3, p = 0.4).

Children carrying either the RTN3 (rs 542998 TC vs. CC OR 1.78, 95% CI 1.276–2.487, p = 0.0006) or the IL-13 (rs 20541 CT vs. TT OR 2.02, 95% CI 1.346–3.03, p = 0.0008) SNPs were more likely than other children to develop CM (Table 2, Figure 2). Furthermore, heterozygosity for the rs2230739 SNP in the ADCY9 gene, encoding an adenylate cyclase, was associated with a 50% reduction in the risk of acidosis (AG vs. AA/GG, OR = 0.516, 95% CI 0.302–0.882, p = 0.0129) (Table 2, Figure 2).

Two mutations in the G6PD gene on the X chromosome (202: rs1050828 CT vs. other and 376: rs1050829 CT vs. other) were strongly associated with protection from severe malaria, and with protection from each of the different clinical phenotypes of severe malaria, in heterozygous females (OR = 0.3–0.5; p < 0.05–p < 8e-6) but not in hemizygous males (Table 2). The protection was best explained in the dominant model inheritance of the trait (supplementary Table 2). However, a haplotype analysis using both G6PD markers (202/376: CT [B - enzymatic group], CC [A+ deficiency], and TC [A- deficiency]), indicated no strong evidence of association with protection (P > 0.1; supplementary table 4). Interestingly, polymorphisms in another X-linked gene, namely that encoding the T cell co-stimulatory receptor CD40 ligand (CD40L; CD154), were associated with either an increased (rs3092945: OR (TT vs. CT/CC) = 5.27, 95% CI 1.491–18.621, p = 0.01) or a decreased (rs1126535: OR (TT vs. CT/CC) = 0.331, 95% CI 0.143–0.766, p = 0.006) risk of respiratory distress (supplementary table 3). The haplotypic analysis indicates that having CT haplotypes for rs3092945 and rs1126535 was a risk of developing respiratory distress in females (OR = 1.768, 95%CI 1.027–3.043, p = 0.040; supplementary table 5).

Polymorphisms in three other genes of known immunological function were also associated with altered risk of severe malaria. Carriage of the rs17411697 SNP in the gene encoding IL-1α was associated with an increased risk of acidosis (GT or TT vs. GG, OR = 1.681, 95% CI 1.183–2.382, p = 0.0035), whereas carriage of the rs1800890 SNP in the IL-10 gene was associated with a decreased risk of severe malaria (additive T, OR = 0.747, 95% CI 0.588–0.949, p = 0.0165) but not with any of the individual severe malaria syndromes. Carriage of the rs7935564 SNP in the gene encoding TRIM5 (an E3 ubiquitin-ligase) was associated with an
increased risk of severe malaria (additive A, OR = 1.273, 95% CI 1.042–1.555, p = 0.02).

Discussion

We set out to investigate whether genetic polymorphisms previously linked to altered risk of severe malaria, or implicated in resistance to other acute infections, were linked to risk of severe malaria in children living in the Tanga region of Tanzania. For some of these polymorphisms, there have been discrepancies in published findings, and these could be a result of variation in phenotype definition, sample size differences, choice of controls, village surveys versus hospital-based studies, immune status, differences in linkage disequilibrium patterns between populations [29], and potentially functional polymorphisms being distal from candidate genes and polymorphisms genotyped [30]. To maximise the robustness of any associations we detected, we standardised recruitment procedures using case report forms, pre-defined the criteria for diagnosis of severe malaria and various severe malaria syndromes. In addition, all analyses were adjusted for the ethnicity of the child and their ward of residence, thereby minimising confounding effects and potential false positives arising from population stratification.

The study confirmed the known (~90%) reduction in severe malaria risk conferred by the haemoglobin B (sickle cell) AS genotype [10]. The low frequency of the S allele in the control children (~4.9%) is in keeping with other populations (see http://www.map.ox.ac.uk/) in West Burkina Faso 5.2%, Cameroon

---

Table 2. Results of association between selected SNP and syndromes of severe malaria.

| Phenotype | SNP        | Gene | Maj/Min | Con MAF | Case MAF | Comparison | O     | LCL | UCL | P       |
|-----------|------------|------|---------|---------|----------|------------|-------|-----|-----|---------|
| SM        | rs1800890  | IL10 | A/T     | 0.240   | 0.207    | Additive T | 0.747 | 0.588 | 0.949 | 0.0165  |
| SM        | rs334      | HBB  | A/T     | 0.083   | 0.016    | AT vs. AA/TT | 0.055 | 0.022 | 0.140 | 2.28E-18 |
| SM        | rs7935564  | TRIM5| G/A     | 0.412   | 0.456    | Additive A | 1.273 | 1.042 | 1.555 | 0.0176  |
| CM        | rs334      | HBB  | A/T     | 0.083   | 0.000    | AT vs. AA/TT | 0.000 | NA   | NA   | 1.35E-07 |
| CM        | rs542998   | RTN3 | T/C     | 0.363   | 0.495    | Additive C | 1.781 | 1.276 | 2.487 | 0.0006  |
| CM        | rs20541    | IL13 | C/T     | 0.194   | 0.324    | Additive T | 2.020 | 1.346 | 3.030 | 0.0008  |
| SMA       | Thala      | Thala| A/B     | 0.319   | 0.251    | Additive B | 0.703 | 0.533 | 0.927 | 0.0116  |
| SMA       | rs334      | HBB  | A/T     | 0.083   | 0.021    | AT vs. AA/TT | 0.047 | 0.011 | 0.196 | 3.47E-11 |
| RD        | rs334      | HBB  | A/T     | 0.083   | 0.007    | AT vs. AA/TT | 0.085 | 0.020 | 0.361 | 2.08E-06 |
| Acid      | rs2230739  | ADCY9| A/G     | 0.077   | 0.057    | AT vs. AA/TT | 0.001 | NA   | NA   | 7.07E-14 |
| Acid      | rs17411697 | IL1A | G/T     | 0.156   | 0.222    | GT/TT vs. GG | 1.681 | 1.185 | 2.383 | 0.0035  |

SM = severe malaria, SMA = severe malarial anaemia, CM = cerebral malaria, RD = respiratory distress, Acid = acidosis, MinA = minor allele, MajA = major allele, ConMAF = minor allele frequency in controls, CaseMAF = minor allele frequency in cases, OR = odds ratio, 95% Confidence interval (LCL, UCL), P = P-value; for X chromosome SNPs (rs1126535 (CD40), rs1050829 (G6PD-376), rs1050828 (G6PD-202/A-), analyses are presented for separately for females (F) and males (M), NA not applicable, *.

doi:10.1371/journal.pone.0047463.t002
Table 3. Interaction between alpha-thalassaemia and HbS and severe malaria.

| Phenotype | HbS/thal | OR** | LCL | UCL | P |
|-----------|----------|------|-----|-----|---|
| SM AA/AA  | 1.000    |      |     |     |   |
| SM AA/AB  | 0.945    | 0.687| 1.301| 0.7292|
| SM AA/BB  | 0.587    | 0.342| 1.004| 0.0517|
| SM AS/AA  | 0.115    | 0.039| 0.340| <0.0001|
| SM AS/AB  | 0.092    | 0.031| 0.275| <0.0001|
| SM AS/BB  | 0.115    | 0.014| 0.976| 0.0475|
| SMA AA/AA | 1.000    |      |     |     |   |
| SMA AA/AB | 0.779    | 0.524| 1.157| 0.2162|
| SMA AA/BB | 0.413    | 0.203| 0.839| 0.0145|
| SMA AS/AA | 0.250    | 0.042| 0.528| 0.0031|
| SMA AS/AB | 0.126    | 0.036| 0.437| 0.0011|
| SMA AS/BB | -        | -    | -   | -   |   |

*No significant evidence of a statistical interaction P>0.4, OR = odds ratio, 95% confidence interval (LCL, UCL), P = P-value, SM = severe malaria, SMA = severe malarial anaemia, **adjusted for age, gender and ethnicity.

Human Genetic Polymorphisms and Severe Malaria

### 6.5%, Gambia 7.6%, Ghana 6.5%, Mali 3.8% and East Africa (Kenya 6.4%, Malawi 2.7%).

The α-thalassaemia polymorphism was also associated with severe malaria anaemia, confirming observations in other studies [9,31]. This can be explained by the observation that in α-thalassaemias the mechanical destruction of infected red blood cells that leads to anaemia is slowed or prevented [32]. Similarly, a recent study in Papua New Guinea [31] found that homozygous α-thalassaemia children are protected from the risk of severe malarial anaemia by a lower reduction in haemoglobin concentration compared to children of wild-type genotype through increased erythrocyte count and microcytosis.

The study also confirmed the well-described association between X-linked G6PD deficiency and protection from severe malaria. The geographical distribution of G6PD deficiency offers strong evidence for its selection by malaria; increased oxidative stress in G6PD-deficient red blood cells is assumed to reduce parasite replication and thereby confer protection [reviewed in [8]]. Some studies have reported that both hemizygous males and heterozygous females are protected [33] whereas other studies suggest either that only male hemizygotes are protected [11,34] or that, as observed here, protection is limited to female heterozygotes [35]. These discrepancies may be due to allelic/haplotypic heterogeneity and more detailed resolution of individual alleles will be required to identify true causal relationships [36].

Interestingly, we found evidence that polymorphisms in another X-linked gene (CD40L) were associated with altered risk of respiratory distress, and that a particular CD40L haplotype was particularly associated with increased disease risk in females. By contrast, in The Gambia, males hemizygous for the CD40L-726C (rs17424229) had a reduced risk of developing severe malaria [17]. CD40-L is a stimulatory co-receptor expressed by activated CD4+ T cells, and plays a pivotal role in augmenting T cell mediated immune function. T cell hypo-responsiveness may predispose to failure to clear an infection whereas hyper-responsiveness may lead to immunopathology.

Polymorphism in the adenyl cyclase 9 gene (ADCY9-rs2230739A>G in a heterozygous model) was associated with decreased risk of acidosis. Adenyl cyclase 9 is a component of the stimulatory G protein (Gs) pathway. Inhibition of the Gs signaling pathway in human erythrocytes blocks merozoite invasion and inhibits intracellular parasite maturation [37] suggesting that mutations in genes within this pathway might plausibly be linked to malaria outcomes [38]. Although there was no evidence that adenyl cyclase 9 polymorphisms were associated with severe malaria outcomes in a large study of cases from Malawi and The Gambia [39], SNPs in two other genes in the Gs signal transduction pathway - adenosine receptor 2 (ADORA2A) and G-alpha-s (GNAS) - have been linked to altered risk of severe malaria in multicentre studies in The Gambia, Malawi and Kenya [39,40]. Data from studies on chronic acidosis suggest that the high proton concentrations exerted by acidosis stimulate proton sensitive G-protein-coupled receptors, which are mediated by the cellular cAMP/PKA pathway and it is possible that mutations in Gs would modify this effect [41]. Taken together, these studies suggest that modulation of the Gs signal transduction pathway may modulate the outcome of malaria infection. The number of different associations detected, across different SNPs and loci, suggest that this pathway may be a biologically relevant modulator of host susceptibility to malaria.

The role of IL-10 in limiting the pathological consequences of malaria-induced inflammation is well established [reviewed in [42]]. IL-10 deficient mice infected with normally resolving malaria infections succumb to acute immunopathology [43], high ratios of serum IL-10 to proinflammatory cytokines such as TNF-γ, TNF and IL-12 are associated with positive clinical outcomes [44,45,46] and IL-10-secreting T cells have been correlated with resistance to severe malaria pathology [47,48]. Furthermore, polymorphisms involving the IL-10 promoter region have been associated with both severe malaria outcomes and IL-10 production levels in Kenya [49] and Mozambique [50], and polymorphisms in the IL-10 receptor gene promoter have also been linked to protection against severe malaria in Gabon [51], but the results of a family based study in The Gambia raised questions as to whether associations with IL-10 signalling pathways might be confounded by foetal survival rates or other sources of inheritance bias [26]. Nevertheless, the evidence from the present study reinforces IL-10 signalling as a pathway of interest for regulating the severe outcomes of malaria infection.

In this study, carriage of the rs20541C>T polymorphism was associated with increased risk of developing cerebral malaria; this polymorphism introduces a nonsynonymous change in exon 4 of the gene encoding IL-13. In line with the known role of IL-13 in induction of Th2 responses, rs20541 polymorphisms have also been linked to allergy and autoimmune disease [52,53] as well as altered outcomes of helminth (Schistosome spp) infections [54]. Our data support other studies implicating IL-13 polymorphisms with risk of severe malaria in Thai adults [55,56] and associations between 5q31-q33 haplotypes (which span the IL13 locus) and antimalarial antibody responses [57]; the recurrent link between IL-13 and risk of severe malaria would seem to warrant further investigation.

TRIM5 (an E3 ubiquitin ligase) is an innate immune signalling molecule that activates pro-inflammatory signalling pathways leading to activation of NF-kB and AP-1 [58]. Mutations in TRIM5 have been associated with HIV susceptibility in different populations [reviewed in [59]], presumably explained by the ability of TRIM5α to bind HIV virions and target them for proteosomal destruction [60], but have not previously been linked to malaria susceptibility.

We observed associations between polymorphisms in reticulon 3 (RTN3-rs342998) and increased risk of cerebral malaria.
Reticulon 3 is a ubiquitously expressed endoplasmic reticulum protein and is believed to be involved in membrane trafficking in the early secretory pathway [61]. It is of interest that RTN3 expression has been repeatedly associated with neurodegenerative diseases in humans [62] and that RTN3 is differentially expressed in brains of experimental malaria resistant and susceptible strains of mice infected with *Plasmodium berghei* ANKA [63].

**Conclusions**

This study confirms previously known genetic associations with protection from severe malaria (HbS, G6PD and α- thalassemia). The study also identifies two X-linked genes associated with altered risk of severe malaria in females, identifies mutations in ADCY9, IL1A and CD40L as being associated with altered risk of severe respiratory distress and acidosis, both of which are characterised by high serum lactate levels, and also identifies two novel (IL-13 and RTN3) genetic associations with cerebral malaria. The RTN3 and TRIM5 associations draw attention to the potential role of intracellular protein trafficking and degradation in the pathogenesis of severe malaria but further studies are needed in areas of differing malaria epidemiology to replicate these findings and understand their functional consequences. The testing of multiple data sets, from diverse malaria endemic regions, within the MalariaGEN consortium offers a powerful route to validate these genetic associations [64].

**References**

1. Organization WH (2010) World malaria report. Geneva: World Health Organization, Available: http://whqlibdoc.who.int/publications/2010/ 9789241564106_eng.pdf.
2. Organization WH (2010) Weekly epidemiological record. Weekly epidemiological record: 229–236.
3. Organization WH (2010c) Weekly epidemiological record: 85: 461–472.
4. Crawley J, Chu G, Mover G, Nosten F (2010) Malaria in children. Lancet 375: 1468–1491.
5. Organization WH (2011) World Malaria Report 2011
6. Greenwood B, Marsh K, Snow R (1991) Why do some African children develop severe malaria? Parasitol Today 7: 277–281.
7. Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN (2005) Heritability of malaria in Africa. PLoS Med 2: e340.
8. Campino S, Kisvazioki D, Dessein A (2006) Mendelian and complex genetics of susceptibility and resistance to parasitic infections. Semin Immunol 18: 411–422.
9. Enevold A, Alifrangi M, Sanchez JJ, Carneiro I, Reper G, et al. (2007) Associations between alpha-thalassemia and Plasmodium falciparum malaria infection in northeastern Tanzania. J Infect Dis 196: 451–459.
10. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, et al. (2009) Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet 41: 657–665.
11. Guindo A, Fairhurst RM, Doumbo OK, Wellems T, Diallo DA (2007) X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 4: e66.
12. Fry AE, Griffiths MJ, Auburn S, Diakite M, Horton JT, et al. (2008) Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 17: 567–576.
13. Rose JA, Handel IG, Thera MA, Deans AM, Lyle KE, et al. (2007) Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A 104: 17417–17426.
14. Artavans-Tsakonas K, Tongren JE, Riley EM (2003) The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 133: 145–152.
15. Clark TG, Diakite M, Auburn S, Campino S, Fry AE, et al. (2009) Tumor necrosis factor and lymphotoxin-alpha polymorphisms and severe malaria in African populations. J Infect Dis 199: 569–575.
16. Moekenbaups PP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen KR, et al. (2008) Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 199: 184–188.
17. Saberi P, Usen S, Farhadian S, Jallow M, Doherty T, et al. (2002) CD40L association with protection from severe malaria. Genes Immun 3: 286–291.
18. Stevenson MM, Riley EM (2004) Innate immunity to malaria. Nat Rev Immunol 4: 169–180.

**Supporting Information**

**Table S1** List of all candidate single nucleotide polymorphisms. (DOCX)
**Table S2** G6PD associations with malaria phenotypes. (DOCX)
**Table S3** CD40LG associations with malaria phenotypes. (DOCX)
**Table S4** Haplotypic analysis of G6PD. (DOCX)
**Table S5** Haplotypic analysis of CD40LG. (DOCX)

**Acknowledgments**

We acknowledge our colleagues at the Joint Malaria Programme (JMP); a collaboration between the National Institute for Medical Research (NIMR), Kilimanjaro Christian Medical College (KCMMC), the London School of Hygiene & Tropical Medicine (LSHTM), and the Centre for Medical Parasitology,University of Copenhagen (CMP).

**Author Contributions**

Conceived and designed the experiments: MC EMR HR CD. Performed the experiments: AM BN GM HW SGC CM RO KRR AJ HR CD. Analyzed the data: AM TGC NS CD. Contributed reagents/materials/analysis tools: KRR MC SGC. Wrote the paper: AM TGC EMR HR CD.
43. Linke A, Kuhn R, Müller W, Honarvar N, Li C, et al. (1996) Plasmodium berghei: differential susceptibility of gene-targeted mice deficient in the GNAS locus with severe malaria. Hum Genet 124: 499–506.
44. Velavan TP, Byakuyaiczki B, Kremsner PG, Kun FF (2012) Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 64: 87–95.
45. Cui L, Jia J, Ma CF, Li SY, Wang YF, et al. (2012) IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin Biochem 45: 283–288.
46. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43–59.
47. Grant AV, Araujo MI, Ponte EV, Oliveira RR, Gao P, et al. (2012) Functional polymorphisms in IL13 are protective against high Schistosoma mansoni infection intensity in a Brazilian population. PLoS One 7: e35863.
48. Naka I, Nishida N, Patarapotikul J, Nuchinop Th, Tokumaga K, et al. (2009) Identification of a haplotype block in the 5q31 cytokine gene cluster associated with the susceptibility to severe malaria. Malar J 8: 232.
49. Ohashi J, Naka I, Patarapotikul J, Hananantachat H, Looareesuwan S, et al. (2003) A single-nucleotide substitution from C to T at position -1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes Immun 4: 529–534.
50. Carpenter D, Abushama H, Bercezky S, Farnert A, Roeth O, et al. (2007) Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol 68: 165–169.
51. Velavan TP, Byakuyaiczki B, Kremsner PG, Kun FF (2012) Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 64: 87–95.
52. Cui L, Jia J, Ma CF, Li SY, Wang YF, et al. (2012) IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin Biochem 45: 283–288.
53. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43–59.
54. Grant AV, Araujo MI, Ponte EV, Oliveira RR, Gao P, et al. (2012) Functional polymorphisms in IL13 are protective against high Schistosoma mansoni infection intensity in a Brazilian population. PLoS One 7: e35863.
55. Naka I, Nishida N, Patarapotikul J, Nuchinop Th, Tokumaga K, et al. (2009) Identification of a haplotype block in the 5q31 cytokine gene cluster associated with the susceptibility to severe malaria. Malar J 8: 232.
56. Ohashi J, Naka I, Patarapotikul J, Hananantachat H, Looareesuwan S, et al. (2003) A single-nucleotide substitution from C to T at position -1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes Immun 4: 529–534.
57. Carpenter D, Abushama H, Bercezky S, Farnert A, Roeth O, et al. (2007) Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol 68: 165–169.
58. Velavan TP, Byakuyaiczki B, Kremsner PG, Kun FF (2012) Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 64: 87–95.
59. Cui L, Jia J, Ma CF, Li SY, Wang YF, et al. (2012) IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin Biochem 45: 283–288.
60. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43–59.
61. Grant AV, Araujo MI, Ponte EV, Oliveira RR, Gao P, et al. (2012) Functional polymorphisms in IL13 are protective against high Schistosoma mansoni infection intensity in a Brazilian population. PLoS One 7: e35863.
62. Naka I, Nishida N, Patarapotikul J, Nuchinop Th, Tokumaga K, et al. (2009) Identification of a haplotype block in the 5q31 cytokine gene cluster associated with the susceptibility to severe malaria. Malar J 8: 232.
63. Ohashi J, Naka I, Patarapotikul J, Hananantachat H, Looareesuwan S, et al. (2003) A single-nucleotide substitution from C to T at position -1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes Immun 4: 529–534.
64. Carpenter D, Abushama H, Bercezky S, Farnert A, Roeth O, et al. (2007) Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol 68: 165–169.
65. Velavan TP, Byakuyaiczki B, Kremsner PG, Kun FF (2012) Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 64: 87–95.
66. Cui L, Jia J, Ma CF, Li SY, Wang YF, et al. (2012) IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin Biochem 45: 283–288.
67. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43–59.
68. Grant AV, Araujo MI, Ponte EV, Oliveira RR, Gao P, et al. (2012) Functional polymorphisms in IL13 are protective against high Schistosoma mansoni infection intensity in a Brazilian population. PLoS One 7: e35863.
69. Naka I, Nishida N, Patarapotikul J, Nuchinop Th, Tokumaga K, et al. (2009) Identification of a haplotype block in the 5q31 cytokine gene cluster associated with the susceptibility to severe malaria. Malar J 8: 232.
70. Ohashi J, Naka I, Patarapotikul J, Hananantachat H, Looareesuwan S, et al. (2003) A single-nucleotide substitution from C to T at position -1055 in the IL-13 promoter is associated with protection from severe malaria in Thailand. Genes Immun 4: 529–534.
71. Carpenter D, Abushama H, Bercezky S, Farnert A, Roeth O, et al. (2007) Immunogenetic control of antibody responsiveness in a malaria endemic area. Hum Immunol 68: 165–169.
72. Velavan TP, Byakuyaiczki B, Kremsner PG, Kun FF (2012) Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 64: 87–95.